New Jersey women have been given a second chance in their life thanks to something new Cancer treatment.
Pamela Goldberger, 65, was found to have glioblastoma in 2023. Even with surgery, it is a devastating diagnosis of average survival rates of just 14-16 months.
In an on-camera interview with Fox News Digital, Goldberger shared that her initial symptoms are subtle except for differences in nausea. Until dinner, she used her fork as a knife and a knife as a fork. (See the video at the top of the article.)
After experimental drug testing, fatal brain tumor tumors in humans disappear
Goldberger went to the ER for a neurological examination, including an MRI and CAT scan. Brain tumor.
“It’s pretty devastating news to hear,” she said. “I don’t know what’s going on, but it wasn’t… our world just stopped.”
“We have two little grandchildren [I thought] I wasn’t going to have the opportunity to see them grow. I think that’s devastating. ”
Goldberger has been admitted to the hospital Brain surgery is scheduled A few days later.
Brain cancer patients who received this painkiller live longer, studies show
Surgery is the standard treatment for this highly invasive brain tumor, but the head of the neurosurgery at Cooper University Hospital in Camden, New Jersey, offered Goldberger another option.
He considered inviting Goldberger to take part in a personalized clinical trial. Dendritic cell therapy It could help treat glioblastoma and she agreed to participate.
After the surgery, Goldberger started six weeks. Chemotherapy and radiationand a few weeks later, we began clinical trial cell therapy for 6 weeks. That process was followed by another year of chemotherapy maintenance.
The healing process was “very progressive,” but Goldberger said he began to feel like he was once the oral chemotherapy was over.
Now, two and a half years after her diagnosis, she is alive, healthy and can play tennis several times a week.
Survival rate Treatment for glioblastoma has not changed in 20 years, according to Dr. Joseph Georges, a neurosurgeon at Banner University Hospital in Phoenix, Arizona. According to Dr. Joseph Georges, who led the clinical trials, treatment for glioblastoma has not changed in 20 years.
“It’s a very mutated tumor, and each patient has a different cell population,” he told Fox News Digital. “And tumors are also very good at silencing the body’s immune system from attacking.”
The new treatment primes the immune system to detect and kill tumor cells by creating vaccines directly from patients’ tumors collected during surgery.
“We’re picking up all these different tumor cell types and teaching the immune system how to attack a tumor, even small cells that avoid surgical resection,” Georges said.
Patients with terminal colon cancer conserved by breakthrough treatment
Treatment using dendritic cells collected from patients was administered to 16 people aged 47-73 who were newly diagnosed with glioblastoma, including Goldberger.
After receiving chemotherapy and radiation, the patient received three courses of injections every two weeks and weekly injections of pegylated interferon drugs (a type of protein that helps regulate the immune system).
The Phase 1 clinical trial showed an overall positive result, according to a press release from Diakonos Oncology, the group that developed a treatment called Doc1021 (Dubondencel).
Researchers have a positive immune response and Improved survival rate After treatment. It has also been found to be safe with minimal side effects, even at high doses.
Rare spinal cancer tumor removed through the eyes of a patient at a university hospital
“I hope it’s stable at best and not growing, but I’m actually seeing some of these people on the MRI have disappeared,” Georges told Fox News Digital.
“It’s really amazing.”
Goldberger still checks in regularly with her doctors, but she reported that she felt “good” and played tennis with her grandchildren, had lunch with friends, and enjoyed reading, shopping and traveling.
“I’m living my best life right now, and I’m not limited by not being able to do anything that I want to do,” she told Fox News Digital.
For other glioblastoma patients, we recommend looking for Goldberger Clinical trial opportunities It encourages you to take healing seriously, where available and appropriate.
“I was a really good patient. I did everything my doctor told me to do,” Goldberger said, pointing out that she walked every day, I ate well There was a lot of sleep.
Click here to sign up for our health newsletter
“I was surrounded by the things that made me happy,” she continued. “I spent a lot of time with my grandchildren and my family…and only did what made me happy.”
“I think they’re all summed up as great medical care And this trial is the reason [I’m alive]. And there’s a lot of luck. ”
For health articles, please visit www.foxnews.com/health
Georges agreed that patients with recurrent glioblastoma should look for clinical trials that could be useful.
Diakonos Oncology announced on July 22 that the first patient was administered in a Phase 2 clinical trial of DOC1021. Georges shared that the trial will be available on 20 sites nationwide.
